Management of Unstable INR on Warfarin Therapy

Patient Assessment and Risk Stratification

The American College of Cardiology recommends that patients with warfarin-induced coagulopathy, such as an INR of 8.0-9.1, be managed with vitamin K, and that subsequent rebound elevation, such as an INR of 5.9 on Day 8, indicates warfarin hypersensitivity requiring permanent discontinuation or extreme dose reduction with intensive monitoring 1, 2
Age greater than 65 years increases bleeding risk in patients with INR >6.0, according to the American College of Cardiology 1, 3

The American College of Cardiology recommends considering direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, or apixaban as alternatives to warfarin for patients who are unable to maintain therapeutic INR, due to their more predictable dose-response relationships and lack of requirement for INR monitoring 4

For patients who require warfarin therapy despite demonstrated hypersensitivity, the American College of Cardiology suggests targeting an INR of 2.0-2.5 to minimize bleeding risk, with daily INR monitoring for the first 2 weeks after any dose adjustment, and consideration of genetic testing for CYP2C9 and VKORC1 variants that predict warfarin sensitivity 3

The American College of Cardiology recommends administering oral vitamin K₁ 1-2.5mg for INR elevations between 5.0-9.0 without bleeding, and 3-5mg for INR >9.0, with recheck of INR within 24 hours after vitamin K administration, and IV vitamin K₁ 10mg by slow infusion plus fresh frozen plasma or prothrombin complex concentrate for bleeding with elevated INR 1, 2, 5

The American College of Cardiology advises screening for interacting medications, such as antibiotics, NSAIDs, and aspirin, which can dramatically increase bleeding risk, and recommends consistent daily intake of dietary vitamin K to avoid destabilizing INR 1, 3

The American College of Cardiology recommends that patients with persistent elevation of INR (2.0-3.3) for 8 days after the final dose and second vitamin K administration demonstrate prolonged drug effect, indicating warfarin hypersensitivity 6
The use of subcutaneous vitamin K is not recommended due to its unpredictable and sometimes delayed response compared to oral or IV routes, as suggested by the American College of Cardiology 6
High-dose vitamin K (10mg) should not be used as it may cause warfarin resistance for up to a week if warfarin needs to be restarted, according to the American College of Cardiology 6